Navigation Links
Surviving ovarian cancer: Rutgers scientists attack drug resistant cancer cells
Date:12/9/2013

Scientists at Rutgers University have developed a targeted drug delivery system that they believe could make ovarian cancer more treatable and increase survival rates for the most deadly gynecological cancer in the United States.

Tamara Minko, professor in the Ernest Mario School of Pharmacy and Lorna Rodriguez, professor of obstetrics and gynecology at Rutgers Cancer Institute of New Jersey, say because there is not a good screening method for ovarian cancer, most women with the disease are not diagnosed until after it has metastasized to other organs and surgery and chemotherapy are not as effective.

"Once the ovarian cancer becomes drug resistant we cannot cure it," says Rodriguez an oncologist who provides treatment to ovarian cancer patients. "Circumventing the development of drug resistance is a reasonable approach and very much needed."

The main reason for advanced-stage ovarian cancer, they say, is an out of control protein CD44, which enables cancerous tumors to proliferate and become resistant to conventional drug treatments. The result: a five-year survival rate for patients with advanced-stage ovarian cancer that is only 30 percent.

In a new study published in Clinical Cancer Research, Minko and Rodriguez provide results of animal research in which the cancer is attacked at the genetic level by using small, inhibiting RNA molecules that directly target and decrease the excess CD44 protein in cancer cells while simultaneously treating patients with the anti-cancer drug paclitaxel. This allows cells within the cancerous tumors to be successfully treated even at an advanced stage.

"We expect that the proposed treatment will be especially effective in advanced stages of ovarian cancers, where there are many cancer stem cells in the tumors that resist conventional drug treatment," says Minko.

In their research, scientists at Rutgers created animal models that closely resemble the cancerous tumors found in women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratory mice. They then used a combination of chemotherapy and gene therapy to target the cancer cells directly in order to inhibit growth and prevent metastasis while sparing normal healthy cells. The treatment killed cancerous cells in the mice, shrunk their tumors and left them with fewer side effects.

Since the CD44 protein is expressed on the surface of many cancer stem cells, the approach developed by Rutgers scientists may help in the treatment of other types of cancers. The next step for ovarian cancer research would be to develop a drug for human consumption that could be used in clinical trials. This, they say, could lead to new pharmacological cancer treatments and increase the survival rate of the deadly disease.


'/>"/>

Contact: Robin Lally
rlally@ucm.rutgers.edu
732-932-7084 x652
Rutgers University
Source:Eurekalert

Related medicine news :

1. Former Athlete Credits Sports for Surviving Horrible Car Accident and Lengthy Coma
2. Stage I NSCLC patients who receive radiation therapy are surviving longer
3. Floodmasters 5 Tips to Surviving the Next Hurricane Sandy
4. Too Much Sitting May Lower Odds of Surviving Colon Cancer
5. More Infants Surviving With Serious Heart Defects, Study Finds
6. ParentMagic Inc Releases Enhanced E-Book “Surviving Your Adolescents” Available in iBooks on iOS
7. Study Finds Overweight Young Males Have a Greater Risk of Not Surviving Until Age 55, Making Weight Loss Supplements Like Prescopodene Helpful With Increasing Longevity
8. Surviving a Tornado and Then Facing Homeowner Insurance Battles
9. Parent Magic Inc's "Surviving Your Adolescents" Wins Gold Award in National Parenting Publications Awards 2013
10. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
11. U.S. Panel Rejects Ovarian Cancer Screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 West Pharmaceutical Services, ... solutions for injectable drug administration, today announced that it ... opens on Thursday, October 26, 2017, and will follow ... business expectations at 9:00 a.m. Eastern Time. To participate ... (International). The conference ID is 94093362. ...
(Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
(Date:10/10/2017)... Oct. 10, 2017   West Pharmaceutical Services, Inc. ... for injectable drug administration, today shared the results of ... for improving the intradermal administration of polio vaccines. The ... Summit in May 2017 by Dr. Ondrej Mach ... World Health Organization (WHO), and recently published in the ...
Breaking Medicine Technology: